Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Diamorphine→

Diamorphine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
561-27-3
Molecular formula
C21H23NO5
Molecular weight
369.4 g/mol
Drug class
Semi-synthetic opioid analgesic (diacetylmorphineheroin)
Mechanism of action
A potent opioid agonist. Diamorphine rapidly crosses the blood–brain barrier and is converted to 6-monoacetylmorphine and morphine, which activate opioid receptors, particularly mu-opioid receptors, reducing pain transmission and producing central nervous system depression.
Indications / reported uses
  • Treatment of severe pain associated with surgery, myocardial infarction and terminal illness
  • Relief of dyspnoea in acute pulmonary oedema under the cited UK injectable product information; this is a prescription-controlled opioid with significant respiratory-depression and dependence risks

Sources: UK SmPC — Diamorphine hydrochloride 5 mg injection (updated 13 Nov 2025) · UK SmPC change history — Diamorphine hydrochloride 100 mg injection (updated 12 Nov 2025) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Diamorphine Environmental Risk Assessment (ERA) (the Diamorphine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.